Clinical Trial Update: A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK117 as Monotherapy or in Combination With AK104 [Phase 1]

View source ↗

Summary

The completed Phase 1 trial evaluated the safety, pharmacokinetics, and antitumor activity of AK117 as a standalone therapy or in combination with AK104 in mali…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Neoplasms

Drugs mentioned

• AK104 (PD-1/CTLA-4 bispecific antibody)
• AK117 (AK117)

Snippet

Sponsor: Akesobio Australia Pty Ltd | Conditions: Neoplasms Malignant | Phase 1 | Status: COMPLETED